The operator of Kinney Drugs retail chain sued Takeda Pharmaceutical and Endo International over claims that the pharmaceutical manufacturers allegedly engaged in a pay-to-delay scheme to keep generic versions of Takeda’s anti-constipation drug Amitiza off the market.
Related: Takeda Wants 2nd Circuit To Toss Actos Antitrust Suit
KPH Healthcare Services’ antitrust lawsuit, filed Tuesday, August 3, in the US District Court for the District of Massachusetts, claimed that Japan-based Takeda and its US subsidiary, Takeda Pharmaceuticals USA, made “reverse payments” totaling between US$29 and US$280 million to an Endo subsidiary, Par Pharmaceuticals, to keep the generic from being introduced for over six years.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Biden Administration Supports Antitrust Suit Against FIFA
Mar 18, 2024 by
CPI
Apple in Talks to Incorporate Google’s Gemini AI Amid Antitrust Scrutiny
Mar 18, 2024 by
CPI
Appeals Court Revives Regeneron’s Antitrust Lawsuit Against Novartis Over Vision Treatment
Mar 18, 2024 by
CPI
Apple Responds to Criticism Over EU’s Digital Markets Act Compliance
Mar 18, 2024 by
CPI
Turkey Imposes Interim Measures on Meta Platforms
Mar 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pricing Algorithms
Feb 28, 2024 by
CPI
Pricing Algorithms and Antitrust Enforcement: Sandboxes to the Rescue?
Feb 28, 2024 by
CPI
AI, Algorithmic Pricing, and Collusion
Feb 28, 2024 by
CPI
Competition & Collusion in a World of Algorithmic Pricing: Antitrust Risks & Enforcement Trends
Feb 28, 2024 by
CPI
Pricing Algorithms in Antitrust’s Sights?
Feb 28, 2024 by
CPI